Skip to main content
. 2017 Mar 29;8(24):39177–39184. doi: 10.18632/oncotarget.16640

Figure 3. ANRIL inhibits the paclitaxel sensitivity of LAD.

Figure 3

(A) qRT-PCR assay of ANRILexpression level in LAD tissues (n = 50). (B) qRT-PCR assay of ANRILexpression level in LAD patients insensitive (n = 22) and sensitive (n = 28) to paclitaxel. (C) qRT-PCR assay of ANRILexpression level in A549/Taxol and parental A549 cells transfected with smart silencers. * P < 0.05.